JP2015523365A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523365A5
JP2015523365A5 JP2015520657A JP2015520657A JP2015523365A5 JP 2015523365 A5 JP2015523365 A5 JP 2015523365A5 JP 2015520657 A JP2015520657 A JP 2015520657A JP 2015520657 A JP2015520657 A JP 2015520657A JP 2015523365 A5 JP2015523365 A5 JP 2015523365A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
optionally substituted
item
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520657A
Other languages
English (en)
Japanese (ja)
Other versions
JP6025977B2 (ja
JP2015523365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049119 external-priority patent/WO2014008285A1/en
Publication of JP2015523365A publication Critical patent/JP2015523365A/ja
Publication of JP2015523365A5 publication Critical patent/JP2015523365A5/ja
Application granted granted Critical
Publication of JP6025977B2 publication Critical patent/JP6025977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520657A 2012-07-03 2013-07-02 C型肝炎ウイルスの阻害剤 Active JP6025977B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667806P 2012-07-03 2012-07-03
US61/667,806 2012-07-03
US201361798524P 2013-03-15 2013-03-15
US61/798,524 2013-03-15
PCT/US2013/049119 WO2014008285A1 (en) 2012-07-03 2013-07-02 Inhibitors of hepatitis c virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015220577A Division JP2016041743A (ja) 2012-07-03 2015-11-10 C型肝炎ウイルスの阻害剤

Publications (3)

Publication Number Publication Date
JP2015523365A JP2015523365A (ja) 2015-08-13
JP2015523365A5 true JP2015523365A5 (cg-RX-API-DMAC7.html) 2016-01-07
JP6025977B2 JP6025977B2 (ja) 2016-11-16

Family

ID=48803614

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015520657A Active JP6025977B2 (ja) 2012-07-03 2013-07-02 C型肝炎ウイルスの阻害剤
JP2015220577A Withdrawn JP2016041743A (ja) 2012-07-03 2015-11-10 C型肝炎ウイルスの阻害剤
JP2018111786A Withdrawn JP2018154651A (ja) 2012-07-03 2018-06-12 C型肝炎ウイルスの阻害剤
JP2020085702A Pending JP2020143107A (ja) 2012-07-03 2020-05-15 C型肝炎ウイルスの阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015220577A Withdrawn JP2016041743A (ja) 2012-07-03 2015-11-10 C型肝炎ウイルスの阻害剤
JP2018111786A Withdrawn JP2018154651A (ja) 2012-07-03 2018-06-12 C型肝炎ウイルスの阻害剤
JP2020085702A Pending JP2020143107A (ja) 2012-07-03 2020-05-15 C型肝炎ウイルスの阻害剤

Country Status (40)

Country Link
US (7) US9296782B2 (cg-RX-API-DMAC7.html)
EP (4) EP2870160B1 (cg-RX-API-DMAC7.html)
JP (4) JP6025977B2 (cg-RX-API-DMAC7.html)
KR (3) KR102040023B1 (cg-RX-API-DMAC7.html)
CN (2) CN106117309B (cg-RX-API-DMAC7.html)
AP (1) AP3903A (cg-RX-API-DMAC7.html)
AR (1) AR091661A1 (cg-RX-API-DMAC7.html)
AU (6) AU2013286729B2 (cg-RX-API-DMAC7.html)
BR (2) BR122021012378B1 (cg-RX-API-DMAC7.html)
CA (1) CA2877005C (cg-RX-API-DMAC7.html)
CL (1) CL2014003634A1 (cg-RX-API-DMAC7.html)
CO (1) CO7160104A2 (cg-RX-API-DMAC7.html)
CR (1) CR20150045A (cg-RX-API-DMAC7.html)
CY (2) CY1118379T1 (cg-RX-API-DMAC7.html)
DK (2) DK3159345T3 (cg-RX-API-DMAC7.html)
EA (2) EA033961B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15002066A (cg-RX-API-DMAC7.html)
ES (3) ES2827300T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20161379T1 (cg-RX-API-DMAC7.html)
HU (2) HUE042345T2 (cg-RX-API-DMAC7.html)
IL (4) IL236500B (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02598A (cg-RX-API-DMAC7.html)
LT (2) LT2870160T (cg-RX-API-DMAC7.html)
MD (2) MD4602B1 (cg-RX-API-DMAC7.html)
ME (2) ME03362B (cg-RX-API-DMAC7.html)
MX (2) MX360597B (cg-RX-API-DMAC7.html)
MY (1) MY173342A (cg-RX-API-DMAC7.html)
NZ (2) NZ739248A (cg-RX-API-DMAC7.html)
PE (1) PE20150204A1 (cg-RX-API-DMAC7.html)
PH (3) PH12014502862B1 (cg-RX-API-DMAC7.html)
PL (2) PL3159345T3 (cg-RX-API-DMAC7.html)
PT (2) PT2870160T (cg-RX-API-DMAC7.html)
RS (2) RS55494B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201702950TA (cg-RX-API-DMAC7.html)
SI (2) SI2870160T1 (cg-RX-API-DMAC7.html)
SM (3) SMT201900167T1 (cg-RX-API-DMAC7.html)
TW (1) TWI602822B (cg-RX-API-DMAC7.html)
UA (1) UA119315C2 (cg-RX-API-DMAC7.html)
UY (1) UY34888A (cg-RX-API-DMAC7.html)
WO (1) WO2014008285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6511432B2 (ja) * 2013-03-15 2019-05-15 ギリアード サイエンシーズ, インコーポレイテッド C型肝炎ウイルスの大環状二環式阻害剤
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
CA2934049A1 (en) 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
CA2934537C (en) * 2013-12-23 2022-08-16 Gilead Sciences, Inc. Synthesis of an antiviral compound
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN107250097B (zh) * 2015-02-16 2020-08-07 中央硝子株式会社 含氟α-酮羧酸酯类的实用制造方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2969239T3 (es) 2016-05-27 2024-05-17 Gilead Sciences Inc Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
JOP20170127A1 (ar) 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
EA036176B1 (ru) 2016-09-22 2020-10-09 Астразенека Аб Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
JP2020505952A (ja) * 2017-02-01 2020-02-27 アッヴィ・インコーポレイテッド (±)−2−(ジフルオロメチル)−1−(アルコキシカルボニル)シクロプロパンカルボン酸及び(±)−2−(ビニル)−1−(アルコキシカルボニル)シクロプロパンカルボン酸の酵素的製造方法
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
WO2004093798A2 (en) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
EP2305696A3 (en) 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8278322B2 (en) * 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Hcvns3プロテアーゼ阻害剤
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
WO2008137779A2 (en) 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2686546A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
NZ582096A (en) 2007-06-29 2012-05-25 Gilead Sciences Inc Antiviral compounds that inhibit hepatitis c virus (hcv)
AR068794A1 (es) 2007-06-29 2009-12-09 Gilead Sciences Inc Compuestos antivirales
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2700383A1 (en) 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
WO2009055467A2 (en) 2007-10-24 2009-04-30 Virobay, Inc. Compounds that inhibit protease cathepsin s and hcv replication
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
MX2010006209A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Derivados de quinoxalinilo.
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
WO2009082697A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CA2713005A1 (en) 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Difluorinated tripeptides as hcv serine protease inhibitors
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
CA2714604A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Macrocyclic hcv ns3 protease inhibitors
WO2009114633A1 (en) 2008-03-12 2009-09-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
ES2392611T3 (es) * 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
EP2323981B1 (en) 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
EP2334680A2 (en) 2008-08-20 2011-06-22 Sequoia Pharmaceuticals, Inc. Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
AU2009293494B2 (en) 2008-09-16 2014-04-24 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2010045266A1 (en) 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
EP2364159A4 (en) 2008-10-23 2012-06-13 Concert Pharmaceuticals Inc DETERIORIC MACROCYCLIC INHIBITORS OF NS3 VIRAL PROTEASE
JP5689810B2 (ja) 2008-11-20 2015-03-25 アキリオン ファーマシューティカルズ,インコーポレーテッド C型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
EP2358355B1 (en) 2008-11-21 2013-11-06 Boehringer Ingelheim International GmbH Pharmaceutical composition of a potent hcv inhibitor for oral administration
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20100152103A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2011006631A (es) 2008-12-19 2011-09-06 Gilead Sciences Inc Inhibidores de proteasa ns3 del virus hcv.
DK2382198T3 (da) 2008-12-23 2013-09-30 Janssen Pharmaceuticals Inc Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
EP2432318A4 (en) 2009-05-22 2012-11-21 Sequoia Pharmaceuticals Inc NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2459554B1 (en) 2009-07-31 2013-09-18 Cadila Healthcare Limited Substituted benzamide derivatives as glucokinase (gk) activators
EP2470189A4 (en) 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
CN105001302A (zh) 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
US20110312973A1 (en) 2010-03-10 2011-12-22 Bernd Liepold Solid compositions
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
EP2576564A4 (en) 2010-06-07 2014-01-22 Abbvie Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012037259A1 (en) 2010-09-15 2012-03-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012040040A1 (en) 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
TWI523658B (zh) * 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之hcv絲胺酸蛋白酶抑制劑
US20120095211A1 (en) 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
CN103717067A (zh) 2010-12-14 2014-04-09 默沙东公司 制备大环内酰胺的方法与中间体
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012166459A1 (en) 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
MX2014001945A (es) 2011-08-19 2014-03-27 Merck Sharp & Dohme Procedimiento e intermedios para la preparacion de macrolactamas.
WO2013066753A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Compositions useful for the treatment of viral diseases
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
US20140037719A1 (en) 2012-01-12 2014-02-06 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent hcv inhibitor
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ, インコーポレイテッド C型肝炎ウイルスの大環状二環式阻害剤

Similar Documents

Publication Publication Date Title
CN102239164B (zh) 2h-色烯化合物及其衍生物
JP2012513479A5 (cg-RX-API-DMAC7.html)
KR20220026538A (ko) 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체
JP2011528713A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
CN104136433B (zh) 具有杂三环部分的抗病毒化合物
RU2016150326A (ru) Производные изоиндолина для применения в лечении вирусной инфекции
JP2011518835A5 (cg-RX-API-DMAC7.html)
JP2013056886A5 (cg-RX-API-DMAC7.html)
JP2017526730A (ja) Toll様受容体モジュレーターの固体形態
JP2007532474A5 (cg-RX-API-DMAC7.html)
JP2011523412A5 (cg-RX-API-DMAC7.html)
IL170894A (en) Antiviral phosphonate analogs
JP2013514359A5 (cg-RX-API-DMAC7.html)
MY154683A (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
RU2011141559A (ru) Ингибиторы серинпротеазы
TW201116540A (en) Therapeutic antiviral peptides
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
CN107105660A (zh) 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
JP2014514290A5 (cg-RX-API-DMAC7.html)
JP2015522018A5 (cg-RX-API-DMAC7.html)
JP2010505865A5 (cg-RX-API-DMAC7.html)
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
JP2016516069A5 (cg-RX-API-DMAC7.html)
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами